Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib

Expert Review of Anticancer Therapy

Volumn 11, Issue 12, 2011, Pages 1807-1816

  Cabibbo, Giuseppe ^a   Rolle, Emanuela ^b   De Giorgio, Massimo ^c   Genco, Chiara ^a   Pressiani, Tiziana ^d   Spada, Francesca ^e   Sacco, Rodolfo ^f,g  

^a UNIVERSITY OF PALERMO   (Italy)

^b Azienda Ospedaliero Universitaria Molinette San Giovanni Battista   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^f UNIVERSITY HOSPITAL OF PISA   (Italy)

^g UNIVERSITY OF FOGGIA   (Italy)

Author keywords

cirrhosis; hepatocellular carcinoma; liver cancer; management; sorafenib; systemic therapy; treatment

Indexed keywords

PLACEBO; SORAFENIB;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CONSTIPATION; DESQUAMATION; DIARRHEA; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MOLECULAR PATHOLOGY; NAUSEA; OVERALL SURVIVAL; PROGNOSIS; QUALITY OF LIFE; RASH; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SKIN DISEASE; SYSTEMIC THERAPY; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE MANAGEMENT; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PYRIDINES;

EID: 82355171774     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.139     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 11, 191-207 (2007). (Pubitemid 46829971)
3. Ahmed F, Perz JF, Kwong S, Jamison PM, Friedman C, Bell BP. National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev. Chronic Dis. 5(3), A74 (2008).
4. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J. Gastroenterol. 40, 225-235 (2005). (Pubitemid 40613379)
5. Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126, 1005-1014 (2004). (Pubitemid 38451172)
6. Cabibbo G, Craxì A. Hepatocellular cancer: Optimal strategies for screening and surveillance. Dig. Dis. 27(2), 142-147 (2009).
7. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907-1917 (2003). (Pubitemid 37518510)
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37, 429-442 (2003). (Pubitemid 36152543)
9. Lopez PM, Villanueva A, Llovet JM. Systematic review: Evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment. Pharmacol. Ther. 23, 1535-1547 (2006). (Pubitemid 43727460)
10. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
11. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
12. Schwarz RE, Abou-Alfa GK, Geschwind JF et al.; American Hepato-Pancreato- Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: Expert consensus statement. HPB (Oxford) 12(5), 313-320 (2010).
13. Bruix J, Sherman M. AASLD Practice Guideline. Management of hepatocellular carcinoma: An update. Hepatology 53(3), 1020-1022 (2011).
14. Garcia-Tsao G, Lim JK; Members of Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am. J. Gastroenterol. 104(7), 1802-1829 (2009).
15. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60, 646-649 (1973).
16. Cabibbo G, Palmeri L, Palmeri S, Craxì A. Should cirrhosis change our attitude towards treating non-hepatic cancer? Liv. Int. doi:10.1111/j.1478- 3231 .2011.02629.x (2011) (Epub ahead of print).
17. Cabibbo G, Enea M, Attanasio M et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51, 1274-1283 (2010).
18. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis. 19(3), 329-338 (1999).
19. Cottone M, Virdone R, Fusco G et al. Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology 96(6), 1566-1571 (1999).
20. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet 373(9664), 614-616 (2009).
21. Samuel M, Chow PKH, Chan Shih-Yen E et al. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst. Rev. 1, CD001199 (2009).
22. Lau WY, Lai ECH. Hepatocellular carcinoma: Current management and recent advances. Hepatobiliary Pancreat. Dis. Int. 7, 237-257 (2008). (Pubitemid 351895383)
23. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42, 1208-1236 (2005). (Pubitemid 43112690)
24. Llovet JM, Real MI, Montaña X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359(9319), 1734-1739 (2002). (Pubitemid 34607087)
25. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study. Int. J. Clin. Pract. 64(8), 1034-1041 (2010).
26. Marrero JA, Lencioni R, Kudo M et al. Global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. J. Clin. Oncol. 29(Suppl.), (2011) (Abstract 4001).
27. Peck-Radosavljevic M, Greten TF, Lammer J et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 22(4), 391-398 (2010).
28. Burak KW. Candidacy for sorafenib in HCC patients: Is there a slippery slope beyond a SHARP edge? Oncology (Williston Park) 25(3), 296, 298, 300 (2011).
29. Bolondi L, Caspary W, Bennouna J et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the SHARP trial. Presented at: Gastrointestinal Cancers Symposium. Orlando, FL, USA, 25-27 January 2008.
30. Cabibbo G, Di Marco V, Cammà C et al. Sorafenib for hepatocellular carcinoma: A practice experience. ILCA 2010 Book of Abstracts 162 (2010).
31. Di Maio M, Daniele B, Perrone F. Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. Nat. Rev. Clin. Oncol. 6(9), 505-506 (2009).
32. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9), 1001-1011 (2008).
33. Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4, 1-10 (1999). (Pubitemid 29102450)
34. Curt GA, Breitbart W, Cella D, Scherr SL, Portenoy RK, Vogelzang NJ. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(5), 353-360 (2000).
35. Pressiani T, Rimassa L, Boni C et al. Phase II randomized trial on dose-escalated sorafenib versus best supportive care in patients with advanced hepatocellular carcinoma with disease prosgression on prior sorafenib treatment. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 4115).
36. Kudo M, Imanaka K, Chida N et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer (2011) (In Press).
37. Erhardt A, Kollgs FT, Dollinger M et al. Sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma - final results of the Socrates trial. J. Hepatol. 54, S35 (2011).
38. Chung Y, Kim B, Chen C et al. Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim safety and efficacy analysis. J. Clin. Onc. 28(Suppl.), 4026 (2010).
39. Sinakos E, Dedes I, Papalavrentios L, Drevelegas A, Akriviadis E. Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma. Scan. J. Gastroenterol. 45, 511-512 (2010).
40. Dufour JF, Hoppe H, Heim MH et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patient with hepatocellular carcinoma: Results of a Phase I study. Oncologist 15, 1198-1204 (2010).